Stewart W. Strong - 17 May 2024 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Role
President, Global Hospital
Signature
/s/ Thomas V. Powers, attorney-in-fact for Mr. Strong
Issuer symbol
HAE
Transactions as of
17 May 2024
Net transactions value
-$113,509
Form type
4
Filing time
21 May 2024, 18:01:56 UTC
Previous filing
17 May 2024
Next filing
29 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HAE Common Stock Tax liability $27,187 -284 -1.8% $95.73 15,324 17 May 2024 Direct F1, F2
transaction HAE Common Stock Award +2,872 +19% 18,196 17 May 2024 Direct F2, F3, F4
transaction HAE Common Stock Options Exercise $126,773 +2,241 +12% $56.57 20,437 20 May 2024 Direct F2, F5
transaction HAE Common Stock Tax liability $147,849 -1,555 -7.6% $95.08 18,882 20 May 2024 Direct F2, F5, F6
transaction HAE Common Stock Sale $65,245 -686 -3.6% $95.11 18,196 20 May 2024 Direct F2, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HAE Non-qualified Stock Option (Right to Buy) Award $0 +6,313 $0.000000 6,313 17 May 2024 Common Stock 6,313 $95.73 Direct F7
transaction HAE Non-qualified Stock Option (Right to Buy) Options Exercise $0 -2,241 -50% $0.000000 2,242 20 May 2024 Common Stock 2,241 $56.57 Direct F5, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
F2 This number includes unvested RSUs previously reported.
F3 The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
F4 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F5 Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).
F6 Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.
F7 Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.
F8 Reflects options granted on May 18, 2021 that vest in annual increments of 25% beginning on the first anniversary of the date of grant.